| Title |
Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome
|
|---|---|
| Published in |
Advances in Therapy, December 2015
|
| DOI | 10.1007/s12325-015-0273-6 |
| Pubmed ID | |
| Authors |
Vladimir V. Brzheskiy, Elena L. Efimova, Tatiana N. Vorontsova, Vladimir N. Alekseev, Olga G. Gusarevich, Ksenia N. Shaidurova, Alla A. Ryabtseva, Olga M. Andryukhina, Tatiana G. Kamenskikh, Elena S. Sumarokova, Eugeny S. Miljudin, Eugeny A. Egorov, Oleg I. Lebedev, Alexander V. Surov, Andrii R. Korol, Illia O. Nasinnyk, Pavel A. Bezditko, Olena P. Muzhychuk, Vladimir A. Vygodin, Elena V. Yani, Alla Y. Savchenko, Elena M. Karger, Oleg N. Fedorkin, Alexander N. Mironov, Victoria Ostapenko, Natalia A. Popeko, Vladimir P. Skulachev, Maxim V. Skulachev |
| Abstract |
This article presents the results of an international, multicenter, randomized, double-masked, placebo-controlled clinical study of Visomitin (Mitotech LLC, Moscow, Russian Federation) eye drops in patients with dry eye syndrome (DES). Visomitin is the first registered (in Russia) drug with a mitochondria-targeted antioxidant (SkQ1) as the active ingredient. In this multicenter (10 sites) study of 240 subjects with DES, study drug (Visomitin or placebo) was self-administered three times daily (TID) for 6 weeks, followed by a 6-week follow-up period. Seven in-office study visits occurred every 2 weeks during both the treatment and follow-up periods. Efficacy measures included Schirmer's test, tear break-up time, fluorescein staining, meniscus height, and visual acuity. Safety measures included adverse events, slit lamp biomicroscopy, tonometry, blood pressure, and heart rate. Tolerability was also evaluated. This clinical study showed the effectiveness of Visomitin eye drops in the treatment of signs and symptoms of DES compared with placebo. The study showed that a 6-week course of TID topical instillation of Visomitin significantly improved the functional state of the cornea; Visomitin increased tear film stability and reduced corneal damage. Significant reduction of dry eye symptoms (such as dryness, burning, grittiness, and blurred vision) was also observed. Based on the results of this study, Visomitin is effective and safe for use in eye patients with DES for protection from corneal damage. Mitotech LLC. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Russia | 1 | 2% |
| Unknown | 62 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 16% |
| Student > Ph. D. Student | 8 | 13% |
| Student > Doctoral Student | 6 | 10% |
| Student > Bachelor | 5 | 8% |
| Student > Master | 4 | 6% |
| Other | 8 | 13% |
| Unknown | 22 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 25% |
| Biochemistry, Genetics and Molecular Biology | 6 | 10% |
| Nursing and Health Professions | 4 | 6% |
| Agricultural and Biological Sciences | 3 | 5% |
| Psychology | 2 | 3% |
| Other | 6 | 10% |
| Unknown | 26 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 December 2023.
All research outputs
#1,668,212
of 25,097,836 outputs
Outputs from Advances in Therapy
#150
of 2,608 outputs
Outputs of similar age
#27,937
of 401,450 outputs
Outputs of similar age from Advances in Therapy
#1
of 32 outputs
Altmetric has tracked 25,097,836 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,608 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 401,450 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.